Headache, pruritis, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the bulevirtide group compared to the control group.
FRIDAY, June 30, 2023 (HealthDay News) For patients with hepatitis D virus (HDV), bulevirtide is associated with a reduction in HDV RNA levels and alanine aminotransferase (ALT) levels, according to a study published online June 22 in the New England Journal of Medicine to coincide with the annual congress of the European Association for